Search

Displaying results 3681 - 3690 of 9132 in total
  1. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells. … Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

  2. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib has a monoisotopic molecular weight of 578.24 Da. … Docirbrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Docirbrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor.

  3. Drug

    Ocadusertib

    go.drugbank.com/drugs/DB21732
    Investigational

    Ocadusertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Ocadusertib is a serine/threonine kinase inhibitor. … Ocadusertib has a monoisotopic molecular weight of 459.19 Da.

  4. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing. … Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.

  5. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  6. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. … It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.

  7. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. … Lubiprostone is a medication used in the management of idiopathic chronic constipation.

  8. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. … [A251385] PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells

  9. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although … GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series

  10. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies.